NIKTIMVO
GrowthmAbBLAINTRAVENOUSINJECTABLEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
NIKTIMVO by Incyte is axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (csf-1r) expressed on monocytes and macrophages. Approved for chronic graft-versus-host disease (cgvhd) after failure of at least two prior lines of systemic therapy in adult. First approved in 2024.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIKTIMVO (axatilimab-csfr) is a monoclonal antibody that blocks Colony Stimulating Factor-1 Receptor (CSF-1R), a key driver of macrophage proliferation and inflammatory signaling. It is administered intravenously and designed to treat conditions driven by pathological macrophage accumulation and activation. The drug represents a novel immunomodulatory approach targeting innate immune pathology.
Growth
Recent FDA approval (August 2024) positions NIKTIMVO in early growth phase with emerging team opportunities and modest competitive pressure (30% intensity).
Mechanism of Action
Axatilimab-csfr is a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) expressed on monocytes and macrophages. Blocking CSF-1R with axatilimab-csfr reduces the levels of these circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophages, as…
Career Relevance
Worked on NIKTIMVO at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.